PTC Therapeutics

Yahoo Finance • 19 days ago

PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. PTC Therapeutics, Inc. is one of them. PTC Therapeutics, Inc. (NASDAQ:PTCT) is reinforcing its position in rare disease innovation with the... Full story

Yahoo Finance • 19 days ago

PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech

Investors looking for growth chances at fair prices often consider methods like the "Affordable Growth" screen, which finds companies showing solid expansion possibility without high costs. This method balances the search for increasing re... Full story

Yahoo Finance • last month

PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock

Investors looking for growth openings often face the task of finding companies with solid expansion ability that have not yet become overpriced by the market. The Affordable Growth strategy handles this by filtering for stocks showing good... Full story

Yahoo Finance • last month

PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital

PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich’s ataxia, with the FDA stating that substantial evidence of efficacy was not demonstrated and that an additional adequ... Full story

Yahoo Finance • last month

Goldman Sachs reiterates Sell rating on PTC Therapeutics stock at $44 target

Investing.com - Goldman Sachs has reiterated its Sell rating and $44.00 price target on PTC Therapeutics (NASDAQ:PTCT), currently trading at $51.56 with a market capitalization of $4.1 billion, following the company’s receipt of a Comple... Full story

Yahoo Finance • last month

PTC Therapeutics stock falls as FDA issues CRL for vatiquinone in FA

Investing.com - PTC Therapeutics (NASDAQ:PTCT), a $4.1 billion market cap biotech company with an EXCELLENT financial health score according to InvestingPro, received a Complete Response Letter (CRL) from the FDA for vatiquinone in Fried... Full story

Yahoo Finance • 2 months ago

PTCT Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of PTC Therapeutics Inc (Symbol: PTCT) crossed above their 200 day moving average of $47.62, changing hands as high as $49.10 per share. PTC Therapeutics Inc shares are currently trading up about 6.4% on th... Full story

Yahoo Finance • 2 months ago

Noteworthy Tuesday Option Activity: CASH, WHR, PTCT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Pathward Financial Inc (Symbol: CASH), where a total of 2,452 contracts have traded so far, representing approximately 245,200 und... Full story

Yahoo Finance • 2 months ago

PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock at a Fair Valuation

Investors looking for growth opportunities at fair prices often consider the "Affordable Growth" strategy, which finds companies with strong growth prospects that are not overvalued. This method looks for stocks with a growth score above 7... Full story

Yahoo Finance • 3 months ago

PTC Therapeutics stock gets Buy rating from UBS ahead of FDA decision

Investing.com - UBS has reiterated a Buy rating and $71.00 price target on PTC Therapeutics (NASDAQ:PTCT), currently trading at $49.85, ahead of the company’s upcoming FDA decision for sepiapterin, a treatment for phenylketonuria (PKU).... Full story

Yahoo Finance • 3 months ago

PTC Therapeutics Gets Marketing Authorization For Sephience In EU To Treat Phenylketonuria

(RTTNews) - PTC Therapeutics, Inc. (PTCT) Monday said that the European Commission has granted marketing authorization for Sephience for the treatment of phenylketonuria (PKU). The company noted that the uthorization includes a broad labe... Full story

Yahoo Finance • 3 months ago

Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches

PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the 10 biotech stocks screaming a buy. On June 17, analysts at Truist Securities initiated coverage of the stock with a ‘Buy’ rating and an $80 price target. The research firm remains bullish... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newactio... Full story

Yahoo Finance • 4 months ago

PTC Therapeutics' SWOT analysis: biotech stock's potential in rare disease market

PTC Therapeutics, Inc. (NASDAQ:PTCT), with a market capitalization of $4.06 billion, is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare disorders. With a diverse portfolio of approved pro... Full story

Yahoo Finance • 4 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newactio... Full story

Yahoo Finance • 5 months ago

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

WARREN, N.J., April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company... Full story

Yahoo Finance • 6 months ago

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter. The list includes Eli Lilly (... Full story

Yahoo Finance • 2 years ago

PTC Therapeutics Recovers From An Ugly Fall After European Officials Reject DMD Drug

PTC stock rose Friday after European regulators voted to withdraw the biotech company's treatment for a severe form of muscular dystrophy. Continue reading... Full story

Yahoo Finance • 2 years ago

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J., Jan. 3, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, at 7:30 a.m... Full story

Yahoo Finance • 2 years ago

Analysts on Wall Street Lower Ratings for These 10 Stocks

In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts on Wall Street Lower Ratings for These 5 Stocks. European financial markets e... Full story